The importance of “disclosure” in relationships between physicians and pharmaceutical companies
DOI:
https://doi.org/10.18778/1899-2226.21.5.07Keywords:
conflict of interest, disclosure, ethical standard, pharmaceutical industryAbstract
The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.
References
AdvaMed. (n.d.) The Physician Sunshine Act and you. http://advamed.org/res.download/60
Agrawal, S., Brennan, N., & Budetti, P. (2013). The Sunshine Act—effects on physicians. New England Journal of Medicine, 368(22), 2054–2057.
American Medical Association. (n.d.). Sunshine Act FAQs. http://www.amaassn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financialtransparency-reports/sunshine-act-faqs.page?
Belluz, J. (2014, September 30). Doctors and hospitals got at least $3.5 billion from industry in just five months. Vox. http://www.vox.com/2014/9/30/6868897/you-can-now-search-for-your-doctors-pharma-payments-online-sunshine-act
Campbell, E. C., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, D., (2007). A National Survey of Physician – Industry Relationships. The New England Journal of Medicine, 356, 1742–1750.
CBOS [Centre for Public Opinion Research]. (1999). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.
CBOS [Centre for Public Opinion Research]. (2013). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.
CBOS [Centre for Public Opinion Research]. 2016. Społeczne oceny uczciwości i rzetelności zawodowej [Social evaluation of honesty and professional integrity]. Warszawa: CBOS.
Centers for Medicare & Medicaid Services. (n.d.) Fact Sheet for Physcians, https://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet .pdf
Centers for Medicare & Medicaid Services. (n.d.) Open Payments Data Summary. https://openpaymentsdata.cms.gov/summary
Ciadini, R. (2003). Wywieranie wpływu na ludzi. Teoria i praktyka. Gdańsk: Gdańskie Wydawnictwo Psychologiczne.
The CMS Blog. (2016). CMS Releases Third Year of Open Payments Data. https://blog.cms.gov/2016/06/30/cms-releases-third-year-of-open-payments-data/
Dhuri, S. (2013). Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act. https://pharmapromotional.wordpress.com/2013/09/30/comparison-of-the-french-sunshine-act-loi-bertrand-law-and-the-us-sunshine-act/
Hajnosz, I., & Wróblewski, H. (2007). To jak pan korumpował lekarza. Gazeta Wyborcza, 182, p. 6.
Halperin, E. C., Hutchison, P., & Barrier Jr, R. C. (2004). A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology • Biology • Physics, 59(5), 1477–1483.
INFARMA. (2008). Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego [Code of Good Practice of the Pharmaceutical Industry]. http://www.infarma. pl/assets/files/etyka/KodeksDobrych Praktyk_Wyd_2_201014_PL.PDF
INFARMA. (2015). Kodeks przejrzystości [Transparency Code], http://www.kodeksprzejrzystosci.pl/assets/files/etyka/Kodeks_Przejrzystosci_wydanie_5.pdf
INFARMA. (2015–2017). Raport przejrzystości. http://www.kodeksprzejrzystosci.pl/raporty/
INFARMA. (2016). Czym jest Kodeks Przejrzystości. http://www.kodeksprzejrzystosci.pl/kodeks-przejrzysto%C5%9Bci/
Kruczkowska, M. (2013). Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał. Gazeta Wyborcza, 172, 8.
Lieb, K., & Scheurich, A. (2014). Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One, 9(10). doi: 10.1371/journal.pone.0110130
Lizut, M. (2006). Jak ustawić lekarza. Gazeta Wyborcza, 120, 4.
Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.
Makowska, M. (2012). Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego. Prakseologia, 152, 125–144.
Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.
Markowska, M., & Jasiński, Ł. (2017). Znaczenie „przejrzystości” w relacjach lekarzy z firmami farmaceutycznymi. Annales. Ethics in Economic Life, 20(1), 95–109.
McDermott, Will & Emery. (2014). Snapshot of sunshine rules in EU countries for the pharmaceutical industry. http://documents.jdsupra.com/beee41ce-968c-484e-9eca-73d39615efb1.pdf
Orlowski, J. P., & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest, 102(1), 270–273.
Pham-Kanter, G., Alexander, G. C., & Nair, K. (2012). Effect of physician payment disclosure laws on prescribing. Archives of Internal Medicine, 172(10), 819–821.
PolicyMed. (2016). Open Payments Data Summary. http://www.policymed.com/2016/06/open-pay ments-2015-data-released.html
Prozilo Life Sciences. (2015). Ready or Not, Full Speed Ahead for the Global Transparency Movement. https://s3-us-west-2.amazonaws.com/porzio/media/1432/porziols-white-paper_august-2015.pdf
Rabij, M., (2014). Lekarz zdalnie sterowany. Newsweek Polska, 2, 32–35.
Szymborski, T. (2003). Kasa fundacji zabytków. Rzeczpospolita, 123, A1–A4.
Wazana, A. (2000). Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of American Medical Association, 283(3), 373–380.
Zverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach. http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach/Stranky/default.aspx
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Annales. Etyka w Życiu Gospodarczym
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
